Weekly Enforcement Report: All Quiet on the Laboratory Front
Though labs were again absent from recent key enforcement actions, sentences were handed down in other healthcare-related cases.
Though labs were again absent from recent key enforcement actions, sentences were handed down in other healthcare-related cases.
Though last week’s cases didn’t involve labs or lab testing, most were FCA-related issues including inflated claims.
Last week saw the usual False Claims Act and kickback-related charges, with the biggest action involving urine drug testing.
Recent OIG report suggests some labs might have gamed Medicare coverage rules in 2020 by billing for unusually high numbers of such tests.
While labs were absent from recent enforcement actions, last week saw kickback schemes involving DME companies and a medical device company.